This transporter can be the target of Canaglifozin, a SGLT2 inhibitor typically used to treat diabetes mellitus: in fact, as showed in PDAC xenograft models, Canaglifozin can reduce tumor growth and increase tumor sensitivity to PIK3 inhibitors (Hopkins et al., 2018). This evidence concerns the gene SLC5A2 and neoplasm.